Key Market Is Likely to Experience a Tremendous Growth by 2023


Posted June 12, 2019 by parag_bir

Heart Failure Market research Report aims to study the current Heart Failure industry and forecasts the market by the end of 2023. This market research provides detailed analysis on the factors influencing the development of Heart Failure industry.

 
Global Heart Failure Market Synopsis:

The Global “Heart Failure Market” research 2019 highlights the major details and provides in-depth analysis of the market along with the future growth, prospects and Industry demands analysis explores with the help of complete report with 50 Pages, figures, graphs and table of contents to analyze the situations of global Heart Failure Market and Assessment to 2023.

This report studies the Global Heart Failure Market over the forecast period of 2019 to 2023. The Global Heart Failure Market is expected to grow at an impressive Compound Annual Growth Rate (CAGR) from 2019 to 2023.

Get Sample Study Papers of “Global Heart Failure Market” @ https://www.businessindustryreports.com/sample-request/162959 .

Heart failure is a serious condition and is progressive. It affects the quality of life for patients and places an economic burden on healthcare systems. Despite advancement for the control of cardiovascular diseases such as myocardial infarction, the prevalence of Heart Failure is on the rise. However, the accurate estimate of disease burden is difficult to gauge due to a large number of patients with asymptomatic left ventricular (LV) dysfunction.

Increasing disease prevalence and unmet medical needs are projected to boost the growth of the Heart Failure market. Drivers of the market are poor diet, lack of exercise, changing lifestyles, increasing stress, unhealthy weights, and increasing smoking and alcohol consumption. Diseases that have synergistic effect on prevalence of Heart Failure such as coronary artery diseases, sleep apnea, heart defects, irregular heartbeats, diabetes mellitus, obesity, and kidney problems are also propelling the Heart Failure market.

Regionally, North America and Europe dominate the market. The prevalence of heart disease is high in countries in Eastern Europe and is increasing in some countries in Asia and South America. Factors contributing to the growth of the heart failure market are increasing incidence of cardiac disorders, aging population, lack of exercise, diet containing high fat and salt content, stress, increasing alcohol consumption, and smoking.

MajorPlayers profiled in the Heart Failure Market report incorporate: Boston Scientific Corporation, Pfizer, GlaxoSmithKline plc, Novartis International AG, Bristol-Myers Squibb Company, Merck Sharp &Dohme.

Latest Industry News

1 Boston Scientific Europe announced the launch of the HeartLogic™ Heart Failure Diagnostic in Europe. With this launch, the first and only diagnostic tool that enables proactive heart failure (HF) care is now available for patients in select countries across Europe including Italy, Spain, UK, Germany, Austria and Switzerland, with more to follow in the coming months. At present, heart failure affects more than 15 million people in Europe and accounts for approximately 3 million hospitalisations and numerous deaths each year.1 The HeartLogic diagnostic provides continuous measurement of early worsening signs of heart failure by combining data from sensors evaluating heart sounds, respiration rate and volume, thoracic impedance, heart rate and activity. HeartLogic’s unique algorithm is built into the Resonate and next generation Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) and implantable cardiac defibrillators (ICDs).

2 Novartis announced results of the landmark PIONEER-HF trial showing that in-hospital initiation of Entresto tablets provided superior benefit compared to enalapril-a heart failure medication commonly used-in patients with HFrEF who had been stabilized following admission for an acute decompensation heart failure (ADHF) event. Patients on Entresto in PIONEER-HF had a 29% greater reduction in time-averaged N-terminal pro-B-type natriuretic peptide (NT-proBNP) at weeks 4 and 8 (the primary endpoint) compared to enalapril patients (95% CI: 0.63, 0.81; P
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Business Industry Reports
Phone +1-9376349940
Business Address Renuka Apartment
Pune
Country India
Categories Health , Medical , Services
Tags boston scientific corporation , glaxosmithkline plc , heart failure , heart failure forecast , heart failure industry analysis , heart failure market , novartis international ag , pfizer
Last Updated June 12, 2019